



Melinta Therapeutics

The Antibiotics Company

January 10, 2018

Dan Wechsler, CEO

Cautionary Note Regarding Forward-looking Statements

- This presentation contains forward-looking statements that involve a number of risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
- You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. We are under no obligation (and expressly disclaim any such obligation) to update or revise any forward-looking statement that may be made from time to time, whether as a result of new information, future developments or otherwise.
- Risks and uncertainties for Melinta Therapeutics, Inc. (the “Company”) are more fully described in the Company’s filings with the SEC, including in its most recently filed Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q and its definitive proxy statements filed with the SEC in October and December 2017.

Creating a Pure-play Antibiotics Leader



- Founded on Nobel Prize-winning discovery
- Received 1st FDA approval (Baxdela)



- Reverse merged in 2017 to list on Nasdaq (MLNT) with >\$150 million of capital



- Acquired three marketed antibiotics and pipeline
- Added strong ID-focused team

***Leading Pure-play Antibiotics Pipeline from Discovery to Commercial;
Significant Antibiotics-focused Talent Within Single Organization;
>\$1 Billion US Peak Sales Potential From 4 Currently Approved Products***



The New Melinta





Significant Commercial Opportunity

>\$1 Billion US Sales Potential for Current Indications



For ABSSSI patients at risk for mixed infections in the hospital, community or ED



For Gram (+) ABSSSI in the ED or community



For cUTI in the hospital

**Minocin®
(minocycline)
for injection**

For Acinetobacter in the hospital

Unique Market Value for Each Approved Product Optimized by Company Infrastructure and Commitment to Antibiotics


Industry Leading Portfolio and Pipeline

PRODUCT/INDICATION	PRE CLINICAL	PHASE 1	PHASE 2	PHASE 3	NDA Submitted	FDA Approved	EMA Submitted	EMA Approved	
Baxdela Acute Bacterial Skin and Skin Structure Infections (ABSSSI)	[Blue bar spanning Pre-Clinical to FDA Approved]								
Vabomere Complicated Urinary Tract Infections (cUTI)	[Blue bar spanning Pre-Clinical to EMA Submitted]								
Orbactiv ABSSSI	[Blue bar spanning Pre-Clinical to EMA Approved]								
Minocin IV Serious infections due to select organisms including <i>Acinetobacter</i>	[Blue bar spanning Pre-Clinical to FDA Approved]								
Baxdela Community-acquired Bacterial Pneumonia (CABP)	[Teal bar spanning Pre-Clinical to Phase 3]								
Fusidic Acid ABSSSI	[Teal bar spanning Pre-Clinical to Phase 2]								
Solithromycin CABP	[Teal bar spanning Pre-Clinical to NDA Submitted]								
Radezolid Dermatology	[Orange bar spanning Pre-Clinical to Phase 1]								
ESKAPE "Superbugs"	[Blue bar spanning Pre-Clinical]								

**>\$1 Billion
US Sales
Potential**

**Industry
Leading
Pipeline
to Fuel
Future
Growth**


Successful Out-licensing Offers Potential to Expand Partnerships Across Full Portfolio of Assets



VABOMERE™
meropenem and vaborbactam
for injection (4 g)




Minocin®
(minocycline)
for injection



Global rights to products acquired from The Medicines Company present strong future partnership opportunities

Nobel Prize-winning Discovery Platform



- We own the 3D structure of ribosome (home to >50% of commercial antibiotic classes)
- We created the tools and developed the know-how to exploit the ribosome structure

This technology platform enables us to:

- 1 Engineer improvements in existing classes
- 2 Create novel classes of antibiotics to overcome multidrug-resistant bacteria

***Discovered Radezolid, Currently in Clinical Development for Dermatology;
>10,000 Compounds Created, with 3 Completely New Classes***

Strong Commercial and Medical Affairs Capabilities



Commercial


- Approx. 135 sales representatives selling today
- Significant experience: ~15 years hospital + antibiotics
- A portfolio of products that allows HCPs to address serious infections across continuum of care

Medical Affairs

- More than 3x increase in field-based medical support from ID specialists
- Commitment to antibiotic stewardship
- Appropriate capital to generate and publish data for appropriate access

Leveraging Best Practices and Talent From All Organizations

Experienced, Leading Combined Management Team



Dan Wechsler	CEO	<ul style="list-style-type: none"> >25 years; led Zyvox at Pharmacia; led pharma, generics and OTC at Bausch & Lomb; CEO at Smile Brands
Paul Estrem	CFO	<ul style="list-style-type: none"> >25 years; CFO of multiple business units at Baxter
Sue Cammarata, M.D.	CMO	<ul style="list-style-type: none"> >20 years; development of Cubicin and Zyvox
Erin Duffy, Ph.D.	CSO	<ul style="list-style-type: none"> >20 years; leading expert in structure & function of bacterial ribosome
Juliet Agranoff	SVP, HR	<ul style="list-style-type: none"> >20 years; head of HR for The Medicines Company ID franchise
Lisa DeFrancesco	SVP, IR	<ul style="list-style-type: none"> >15 years; VP investor relations at Allergan
Peter Di Roma	SVP, QA/RA	<ul style="list-style-type: none"> >20 years; regulatory approval of Zyvox and Baxdela
Michael McGuire	SVP, Comm'l	<ul style="list-style-type: none"> >25 years of pharma marketing and anti-infectives
Kevin Conway	VP, Tech Ops	<ul style="list-style-type: none"> >30 years; operational management of Humira and Kaletra launches
Kate Farrington	VP, Compliance	<ul style="list-style-type: none"> >20 years of pharma industry compliance/officer roles



Solid Financial Profile



- ✓ **Sufficient capital to execute key priorities**
- ✓ **Significant value inflection points on near-term horizon**
- ✓ **Ability to leverage industry-leading infrastructure across multiple assets**
- ✓ **Fiscally responsible organization with multiple levers**
- ✓ **Sustainable platform for shareholder value generation**

Well-positioned to Meet Critical Unmet Needs

Company	Multiple Late-stage Indications	Gram-negative Pipeline	Successful Phase 3 Program	Multiple Approved Products	Sustainable Discovery Capabilities
Melinta (MLNT)	✓	✓	✓	✓	✓
Achaogen (AKAO)		✓	✓		
Paratek (PRTK)	✓		✓		
Tetraphase (TTPH)	✓	✓			✓
Nabriva (NBRV)	✓				

Source: Company estimates

Strategy for Long-term Growth and Expansion

DRIVE

Sales of >\$1 billion from four US-approved antibiotics

DEVELOP

Additional indications during 10+ years of market exclusivity for key assets afforded by GAIN Act

DISCOVER


Completely novel anti-infectives leveraging our proprietary, Nobel Prize-winning discovery platform

EXPAND

Ex-US partnerships across entire product portfolio to enhance company value

Continue to Execute Growth-accelerating Business Development Activities

The New Melinta



***Attractive Growth Equity Story;
Robust Antibiotics Pipeline from Discovery to Commercial;
World-class Capabilities***